scholarly journals Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

2008 ◽  
Vol 14 (21) ◽  
pp. 7060-7067 ◽  
Author(s):  
Daniel B. Costa ◽  
Kim-Son H. Nguyen ◽  
Byoung C. Cho ◽  
Lecia V. Sequist ◽  
David M. Jackman ◽  
...  
Keyword(s):  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Egfr Mutated

scholarly journals Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

Lung Cancer ◽  
2015 ◽  
Vol 88 (1) ◽  
pp. 108-111 ◽  
Author(s):  
Deepa Rangachari ◽  
Norihiro Yamaguchi ◽  
Paul A. VanderLaan ◽  
Erik Folch ◽  
Anand Mahadevan ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Egfr Mutated

Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8105-8105
Author(s):  
D. B. Costa ◽  
B. C. Cho ◽  
L. V. Sequist ◽  
G. J. Riely ◽  
B. Halmos ◽  
...  
Keyword(s):  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Egfr Mutated

The tyrosine kinase TEK is differentially expressed in non-small cell lung adenocarcinomas.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
United States ◽  
Tyrosine Kinase ◽  
Lung Adenocarcinoma ◽  
Microarray Data ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Significant Differential Expression ◽  
Lung Cancers ◽  
Lung Adenocarcinomas

Non-small cell lung adenocarcinoma (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the tyrosine kinase TEK in tumors from patients with NSCLC. TEK may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.

Sign in / Sign up

Export Citation Format

Share Document